Quince Therapeutics Inc. (QNCX)
NASDAQ: QNCX
· Real-Time Price · USD
1.72
0.04 (2.38%)
At close: Aug 15, 2025, 2:34 PM
2.38% (1D)
| Bid | 1.68 |
| Market Cap | 92.39M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -60.71M |
| EPS (ttm) | -1.1 |
| PE Ratio (ttm) | -1.56 |
| Forward PE | -1.98 |
| Analyst | Buy |
| Ask | 1.72 |
| Volume | 88,610 |
| Avg. Volume (20D) | 273,046 |
| Open | 1.68 |
| Previous Close | 1.68 |
| Day's Range | 1.63 - 1.72 |
| 52-Week Range | 0.53 - 2.45 |
| Beta | 1.02 |
About QNCX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol QNCX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for QNCX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts2 months ago
+19.17%
Quince Therapeutics shares are trading higher afte...
Unlock content with
Pro Subscription
9 months ago
+19.5%
Quince Therapeutics shares are trading higher after the company reported a year-over-year increase in Q3 EPS results.
3 months ago · seekingalpha.com
Quince Therapeutics: Data In Ataxia-Telangiectasia Scheduled For Early 2026Quince Therapeutics is advancing eDSP for Ataxia-Telangiectasia, leveraging strong prior data in the 6-9 age group and an innovative AIDE platform. Recent insider buying, new analyst coverage with hig...